سعر ساجيتريكسان 2.5مجم 20 قرص 2023

Sagitrixan 2.5 mg film-coated tablets (pack of 20) contain apixaban, an oral direct factor Xa inhibitor anticoagulant, used for stroke prevention in nonvalvular atrial fibrillation and for prevention and treatment of venous thromboembolism.

• Reduction of risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillationPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Prophylaxis of deep vein thrombosis after hip or knee replacement surgery in adultsPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of deep vein thrombosis and pulmonary embolism in adultsPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>1%) in adults are related to bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding; severe hypersensitivity reaction to apixaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: premature discontinuation increases the risk of thrombotic events; consider another anticoagulant if stopped for reasons other than bleeding or end of therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: epidural or spinal hematoma (possible long-term or permanent paralysis) with neuraxial anesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increases the risk of serious, potentially fatal bleeding; risk increased with aspirin/antiplatelets, other anticoagulants, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Combined P-gp and strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir)For patients on 2.5 mg twice daily, avoid coadministration; for 5 or 10 mg twice daily reduce the dose by 50%.DailyMed (U.S. National Library of Medicine)
• Combined P-gp and strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, St John's wort)Avoid concomitant use; decreased apixaban exposure increases the risk of stroke and thromboembolic events.DailyMed (U.S. National Library of Medicine)
• Antiplatelet agents, fibrinolytics, heparin, aspirin, chronic NSAIDsCoadministration increases the risk of bleeding.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are insufficient to inform drug-associated risks; treatment may increase bleeding risk during pregnancy and delivery; no adverse developmental effects in animal studies.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human milk data; apixaban is present in rat milk; breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.